How Lenalidomide Is Used for Multiple Myeloma Treatment

Lenalidomide is one of the most widely used drugs in multiple myeloma, appearing at nearly every stage of treatment: as part of initial combination therapy, as long-term maintenance after stem cell transplant, and in regimens for patients whose disease has returned. Its versatility stems from a dual mechanism that both attacks myeloma cells directly and recruits the immune system against them. Understanding how and when lenalidomide fits into a treatment plan, what side effects to watch for, and how newer drugs build on its foundation helps make sense of a disease whose treatment landscape has changed dramatically over the past two decades.

How Lenalidomide Actually Works Inside the Body

Lenalidomide belongs to a class called immunomodulatory drugs, or IMiDs, which descended from thalidomide. For years, researchers knew these drugs worked against myeloma but could not fully explain why. The breakthrough came in 2014, when two research teams independently showed that lenalidomide binds to a protein called cereblon, part of the cell’s protein-disposal machinery. Once lenalidomide latches onto cereblon, it changes what that machinery targets for destruction. Specifically, it redirects the system to break down two transcription factors, IKZF1 and IKZF3, that myeloma cells depend on to survive and grow.¹² This was a novel concept in drug design at the time: rather than blocking an enzyme or receptor, lenalidomide hijacks an existing disposal system and reprograms its targets.

This mechanism matters practically because it explains both the drug’s effectiveness and some of its limitations. Myeloma cells that lose or reduce their cereblon protein can become resistant, since the drug has nothing to bind to. It also explains why next-generation drugs in the same family are being engineered to grip cereblon more tightly and degrade additional targets.

Immune System Effects Beyond Direct Cell Killing

Lenalidomide does not just poison myeloma cells. It also wakes up the immune system in several ways that help the body fight the cancer on its own. It stimulates T cells to multiply and release signaling molecules, and it activates natural killer (NK) cells, a type of immune cell that can recognize and destroy tumor cells. It also dials down an immune-suppressing signal called PD-1 on both T cells and NK cells, which myeloma cells exploit to hide from immune surveillance.³ On top of that, it disrupts the communication between myeloma cells and the bone marrow environment around them, a crosstalk that normally helps the cancer cells survive and multiply.

These immune effects are part of why lenalidomide works so well in combination with antibody-based drugs. When combined with monoclonal antibodies that tag myeloma cells for destruction, the enhanced NK cell activity lenalidomide provides makes the antibody’s kill signal more effective.⁴ This synergy is a big reason that modern myeloma regimens almost always pair lenalidomide with at least one other drug.

Frontline Treatment for Newly Diagnosed Patients

When someone is first diagnosed with multiple myeloma, one of the earliest decisions is whether they are a candidate for autologous stem cell transplant, a procedure where high-dose chemotherapy wipes out the bone marrow and the patient’s own previously collected stem cells rebuild it. Lenalidomide plays a role on both sides of that decision.

For transplant-eligible patients, the most common induction regimen in many countries combines bortezomib (a proteasome inhibitor), lenalidomide, and dexamethasone (a steroid), known by the shorthand VRd. The goal of induction is to reduce the myeloma burden as much as possible before transplant. A Japanese phase 2 trial of VRd induction illustrated both the regimen’s activity and its intensity: four cycles of VRd achieved a complete or near-complete response in roughly a quarter of patients, though dose reductions were needed in half of those who completed induction due to side effects.⁵ VRd has become the backbone regimen internationally, with the understanding that side effect management is a routine part of treatment.

For patients who are not eligible for transplant, or who choose to defer it, VRd is also used as the primary treatment. But the more exciting recent development is the addition of a fourth drug, daratumumab (an anti-CD38 antibody), creating the quadruplet D-VRd. The landmark PERSEUS trial, which studied transplant-eligible patients, showed that D-VRd cut the risk of disease progression or death by about 58% compared to VRd alone. At four years, roughly 84% of patients on D-VRd were progression-free, compared to about 68% on VRd. Rates of complete response and undetectable residual disease (called MRD-negative status) were also substantially higher with the four-drug combination.⁶

A separate randomized trial, CEPHEUS, confirmed similar benefits in transplant-ineligible or transplant-deferred patients. At nearly five years of follow-up, D-VRd produced significantly deeper responses and lowered the risk of progression or death by 43% compared to VRd.⁷ These results are pushing D-VRd toward becoming the new standard of care for many newly diagnosed patients, regardless of transplant eligibility. Lenalidomide remains the backbone of all of these regimens.

Maintenance Therapy After Transplant

One of the most impactful uses of lenalidomide is as maintenance therapy, taken continuously after a transplant to keep the disease in check for as long as possible. Two landmark trials published in the New England Journal of Medicine established this practice. One found that lenalidomide maintenance nearly doubled median progression-free survival compared to placebo: 41 months versus 23 months.⁸ The other confirmed that starting lenalidomide about 100 days after transplant significantly extended both time to disease progression and overall survival.⁹

Maintenance lenalidomide is typically given at a lower dose than during induction, usually 10 to 15 mg daily for 21 days of a 28-day cycle, though practices vary. Many patients continue maintenance for years, sometimes indefinitely until progression or intolerable side effects. The trade-off is real: maintenance adds toxicity and a small increase in second cancers (discussed below), but the survival benefit is large enough that it has become the standard approach for most transplant recipients.

Relapsed or Refractory Disease

Myeloma almost always comes back eventually, and lenalidomide has a role in relapse treatment too, provided the disease has not already become resistant to it. Lenalidomide-based triplet regimens are considered a standard option for patients whose myeloma returns after initial therapy. Two commonly used combinations are carfilzomib plus lenalidomide and dexamethasone, and daratumumab plus lenalidomide and dexamethasone.¹⁰ These work best in patients whose myeloma still responds to lenalidomide. As more patients receive lenalidomide upfront and as continuous maintenance, however, a growing proportion arrive at first relapse already resistant to it, which is reshaping second-line treatment choices.

For patients whose disease has become refractory to multiple drugs including lenalidomide, options shift toward pomalidomide (a more potent IMiD relative), newer antibody combinations, bispecific antibodies, and CAR-T cell therapy. Lenalidomide’s introduction, along with bortezomib and thalidomide, was one of the developments that significantly improved survival for patients with relapsed and refractory myeloma over the past two decades.¹¹

Side Effects and How They Are Managed

Lenalidomide’s side effect profile is well characterized and, for the most part, predictable enough that doctors can plan around it. The main categories break down as follows:

Low blood counts: Myelosuppression, especially drops in neutrophils (infection-fighting white blood cells) and platelets, is the most common dose-limiting toxicity. Regular blood tests catch this early, and the standard response is a temporary dose reduction or pause. Canadian consensus guidelines and other expert panels have mapped out step-by-step dose adjustment schemes based on how low the counts fall.¹² Growth factor support (G-CSF injections) can also help maintain neutrophil levels.
Blood clots: Lenalidomide increases the risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Myeloma patients already face elevated clot risk, and adding lenalidomide, especially combined with dexamethasone or erythropoiesis-stimulating agents, pushes that risk higher. Guidelines from the International Myeloma Working Group recommend that essentially all patients on lenalidomide receive some form of blood clot prevention, either aspirin for lower-risk patients or a blood thinner for those with additional risk factors.¹³
Fatigue and gastrointestinal symptoms: Tiredness, diarrhea, constipation, and nausea are common but usually manageable. These are among the side effects that affect daily quality of life and often prompt dose adjustments even if they are not medically dangerous.
Rash: Skin reactions occur in a notable minority of patients, ranging from mild rash to more significant reactions that may require dose modification or temporary discontinuation.

The overall pattern is that lenalidomide’s adverse events are predictable and generally manageable with monitoring, supportive care, and dose adjustments as needed.¹⁴ Compared to thalidomide, lenalidomide causes much less sedation and peripheral neuropathy (nerve damage in the hands and feet), which is why it largely replaced thalidomide in clinical practice.

The Second Cancer Question

One of the more unsettling findings about long-term lenalidomide use is a small but real increase in second primary malignancies, meaning new cancers unrelated to myeloma. The Myeloma XI trial, one of the largest to examine this, found that among transplant-eligible patients who received lenalidomide maintenance, the overall incidence of second cancers was about 7.7%, compared to 3.2% in patients who were simply observed without maintenance.¹⁵ Among transplant-ineligible patients, the difference was not statistically significant, though the absolute numbers were higher in both groups.

This risk is taken seriously but is generally considered acceptable given the substantial survival benefit of lenalidomide maintenance. Doctors weigh the individual patient’s risk profile, and ongoing monitoring for new symptoms is part of the long-term follow-up plan. The second cancers reported tend to include hematologic malignancies like myelodysplastic syndrome and solid tumors, though no single cancer type dominates the pattern.

Pregnancy Risk and the REMS Program

Because lenalidomide is structurally related to thalidomide, it carries a serious risk of birth defects and is classified as a known or potential human teratogen. In the United States, lenalidomide is only available through a Risk Evaluation and Mitigation Strategy (REMS) program, which imposes strict requirements on prescribers, pharmacies, and patients to prevent fetal exposure. Patients who can become pregnant must use two forms of contraception and undergo regular pregnancy testing. Studies of the REMS program have found that it does achieve high levels of patient understanding and compliance with these birth control precautions.¹⁶ The REMS program also means that prescriptions require extra steps and cannot simply be called in to a pharmacy, which can be a logistical nuisance for patients but exists for good reason.

Kidney Problems and Dose Adjustments

Multiple myeloma frequently damages the kidneys, and up to half of patients have some degree of kidney impairment at diagnosis. This matters for lenalidomide because the drug is primarily cleared through the kidneys. In people with normal kidney function, about 84% of the dose is recovered unchanged in urine. As kidney function declines, the drug lingers in the body much longer. In patients with moderate to severe kidney impairment, drug exposure can increase by roughly two- to fourfold, and the drug’s half-life extends considerably.¹⁷

The good news is that lenalidomide can still be used safely in patients with impaired kidneys, including those on dialysis, as long as the dose is adjusted downward. Some doctors have historically been too cautious and avoided lenalidomide entirely in these patients, which can mean missing out on an effective treatment. Studies have shown that with proper dose reduction based on kidney function, lenalidomide remains both effective and safe even in patients with very severe renal impairment.¹⁸

Impact on Stem Cell Collection

For patients headed toward transplant, there is a practical wrinkle with lenalidomide-containing induction. Lenalidomide can make it harder to collect enough stem cells for the transplant procedure. A study comparing different induction regimens found that patients who received VRd had lower stem cell yields than those on bortezomib-thalidomide-dexamethasone (VTd), and about 40% of VRd patients required a second round of mobilization. Plerixafor, a drug that helps release stem cells from the bone marrow, was also needed much more frequently in the VRd group.¹⁹

The practical takeaway is that transplant centers now plan stem cell collection early in the treatment course, before too many cycles of lenalidomide have been given. Limiting the number of lenalidomide-containing induction cycles before collection and using plerixafor when needed are standard strategies to avoid mobilization failure.

Living on Lenalidomide Long-Term

Because maintenance therapy can continue for years, the day-to-day experience of taking lenalidomide becomes an important quality-of-life question. The drug is an oral capsule, typically taken once daily on a 21-days-on, 7-days-off schedule, which gives the blood counts a chance to recover during the off week. A pilot study of older myeloma patients on lenalidomide maintenance found that adherence was extremely high, with a median of 98% of prescribed doses taken correctly. Most patients who missed a dose made it up during their scheduled off week.²⁰ The oral formulation is a significant practical advantage over intravenous treatments, particularly for patients who live far from a treatment center or who want to minimize clinic visits.

Chronic fatigue is probably the most common complaint among long-term users and can be hard to separate from the fatigue of the disease itself. Regular blood count monitoring, periodic dose adjustments, and attentive communication between patient and doctor are the main tools for keeping side effects manageable over the long haul.

Generic Lenalidomide

Lenalidomide was historically one of the most expensive cancer drugs on the market, with annual costs in the tens of thousands of dollars in many countries. Generic versions have become available in some markets, raising questions about whether they perform as well. A study comparing original and generic lenalidomide in patients with relapsed or refractory myeloma found similar overall response rates: about 67% for the original and 60% for the generic. Blood-related side effects were comparable between the two, though some non-blood-related side effects differed slightly.²¹ While this was not a randomized comparison and the numbers were modest, the results are broadly reassuring for patients and health systems turning to generics to reduce costs.

Next-Generation Drugs Built on the Same Principle

The discovery of how lenalidomide works opened up an entirely new approach to drug design: engineering molecules that redirect the cell’s own protein-disposal system to destroy disease-causing proteins. Researchers have now developed next-generation agents called CELMoDs (cereblon E3 ligase modulators) that bind cereblon more tightly and degrade its targets more potently than lenalidomide or pomalidomide. Two leading compounds, iberdomide and mezigdomide, are in clinical trials for myeloma patients who have already become resistant to existing IMiDs.²²²³

Preclinical work in lenalidomide- and pomalidomide-resistant cell lines and animal models suggests that both iberdomide and mezigdomide can still trigger myeloma cell death even when the older drugs no longer work. If these results translate into the clinic, CELMoDs could extend the usefulness of the cereblon-targeting approach into later lines of treatment, giving patients who have exhausted current IMiDs another option built on the same biological principle.²⁴ Beyond myeloma, the concept of targeted protein degradation that lenalidomide helped prove is now being applied to other cancers and diseases entirely, making it one of those drugs whose scientific legacy will likely outreach its own therapeutic niche.